FUTURA study: Evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitis;ESTUDO futura: Avaliação da eficácia e segurança do fumarato de rupatadina no tratamento da rinite alérgica persistente

Brazilian Journal of Otorhinolaryngology

Volumn 75, Issue 5, 2009, Pages 673-679

  Mion, Olavo De Godoy ^a   Campos, Regis A ^b,c   Antila, Martti ^d   Rapoport, Priscila Bogar ^e   Rosario, Nelson ^f   De Mello Jr , João Ferreira ^a   Guimarães, Roberto Eustáquio Santos ^g   Mocellin, Marcos ^f   Di Gesu, Giovanni ^h   Solé, Dirceu ⁱ   Wexler, Luc ⁱ   De Mello, João Ferreira ^j   Castro, Fábio Morato ^a   Chavarria, Maria Letícia ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^d Sorocaba Eye Hospital   (Brazil)

^e Medical School of the ABC   (Brazil)

^f FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^g FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^h Santo Antonio Children's Hospital   (Brazil)

ⁱ FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^j State Public Servant Hospital   (Brazil)

more..

Author keywords

Perennial allergic rhinitis; Therapy

Indexed keywords

EID: 73449094569     PISSN: 18088694     EISSN: 18088686     Source Type: Journal    
DOI: 10.1590/S1808-86942009000500011     Document Type: Article

References (22)

1. Bousquet J, Van Cauwenberge P, Khataev N. Allergic Rhinitis and Its Impact on Asthma. J Allergy Clin Immunol. 2001;108:S147-336.
2. Lundback B. Epidemiology of rhinitis and asthma. Clin Exp Allergy 1998;28(S2):3-10.
3. Mion O, Mello Jr, JF Goto EY Lessa, M, Miniti A. The role of rhinitis in chronic otitis media. Otolaryngol Head Neck Surg. 2003;128:27-31.
4. Shoenwetter WF. Allergic Rhinitis: epidemiology and natural history. Allergy Asthma Proc. 2000;21:1-6.
5. Jones NS, Carney AS, Davis A. The prevalence of allergic rhinosinusitis: a review. J Laryngol Otol. 1998;112 (11):1019-30.
6. Bradding P, Feather IH, Wilson S, Holgate ST, Howarth PH. Cytokine immunoreactivity in seasonal rhinitis: regulation by a topical corticosteroid. Am J Respir Crit Care Med. 1995;151:1900-6.
7. Bradding P, Roberts JA, Britten KM, Montefort S, Djukanovic R, Mueller R, et al. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol. 1994;10:471-80.
8. Silberstein DS. Eosinophil function in health and disease. Crit Rev Oncol Hematol. 1995;19:47-77.
9. KleinJan A, Dijkstra MD, Boks SS, Severijnen LA, Mulder PG, Fokkens WJ. Increase in IL-8, IL-10, IL-13, and RANTES mRNA levels (in situ hybridization) in the nasal mucosa after nasal allergen provocation. J Allergy Clin Immunol. 1999;103:441-50.
10. Varney VA, Jacobson MR, Sudderick RM, Robinson DS, Irani AM,Schwartz LB, et al. Immunohistology of the nasal mucosa following allergen-induced rhinitis. Identification of activated T lymphocytes, eosinophils, and neutrophils. Am Rev Respir Dis. 1992;146:170-6.
11. Queralt M, Merlos M, Giral M, Puigdemont A. Dual effect of a new compound, rupatadine, on edema induced by platelet-activating factor and histamine in dogs: comparison with anti-histamines and PAF antagonists. Drug Development Research. 1996;39:12-8.
12. Evans TW, Rogers DF, Aursudkij B, et al. Inflammatory mediators involved in antigen-induced airway microvascular leakage in guinea pigs. Am Rev Respir Dis. 1988;138:395-9.
13. Queralt M, Brazis P, Merlos M, et al. In vitro inhibitory effect of rupatadine on histamine and TNF-alfa release from dispersed canine skin mast cells and the human mast cell line HMC-1. Inflamm Res. 2000;49:355-60.
14. Instituto Brasileiro de Geografia e Estatística. Sin. prelim. censo demogr., Rio de Janeiro, v. 7, p. 1-1 - 5-5, 2000.
15. Broide DH. Molecular and cellular mechanisms of allergic disease. J Allergy Clin Immunol. 2001;108(suppl 2):S65-S71.
16. Salmun LM. Antihistamines in late-phase clinical development for allergic disease. Expert Opin Investig Drugs. 2002;11:259-73.
17. Saint-Martin F, Dumur JP, Perez I, et al. A randomized, double blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 mg and 10 mg), a new PAF and H1 receptor specific histamine antagonist, to loratadine 10 mg in the treatment of season allergic rhinitis. J invest Allergol Clin Inmunol. 2004;14:34-40.
18. Merlos M, Giral M, Balsa D, et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J Pharmacol Exp Ther. 1997;280:114-21.
19. Baroody FM. Allergic rhinitis: broader disease effects and implications for management. Otolaryngol Head Neck Surg. 2003;185:616-31.
20. Guadanõ EM, Serra-Batles J, Meseguer J, et al. Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study. Allergy. 2004;59:766-71.
21. Howarth PH, Salagean M, Dokic D. Allergic rhinitis: not purely a histamine-related disease. Allergy. 2000;55:7-16.
22. Bousquet J, Bindslev-Jensen C, Canonica GW, et al. The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine. Allergy. 2004;59(suppl 77):S4-S16.